argenx

ARGX

Market cap $56.1B

argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net sales in 2025, and there are five late-stage readouts in 2025 that could further improve the long-term outlook. Profitability and robust cash generation add business development as another avenue for growth.

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with an overweight to biotechnology and an underweight to medtech added the most value relative to the Index. Security selection within medtech, life sciences tools & services, and pharmaceuticals detracted from relative results during the period.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geopolitical and trade tensions underscored the strategic importance of supply sources outside China. Constellation Software, a holding company that owns and operates a large portfolio of vertical-market software businesses, detracted from performance.

The volatile sector is seeing greater stability, and these four stocks can profit.

argenx SE ( ARGX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Luc Truyen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Yaron Werber - TD Cowen, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Amy Li - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Samantha Semenkow - Citigroup Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Jacob Mekhael - KBC Securities NV, Research Division Thomas Smith - Leerink Partners LLC, Research Division Douglas Tsao - H.C.

$1.13 billion in third quarter global product net sales  On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. “argenx continues to deliver on our bold innovation agenda, driving transformational impact for patients worldwide,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE for at least 4 weeks Real world data show >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit October 29, 2025, 8:00 AM PT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data further highlighting the efficacy and safety of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) across generalized myasthenia gravis (gMG) patient populations at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM) and Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco from October 29 – November 1, 2025. The data presented feature pivotal Phase 3 results from the ADAPT SERON trial in acetylcholine receptor antibody (AChR-Ab) seronegative patients, interim findings from the ADAPT Jr study in adolescents, a real-world claims analysis showing significantly reduced steroid use among patients treated with VYVGART, long-term outcomes from VYVGART SC treatment with the majority of patients achieving minimal symptom expression (MSE), and a range of other important results.

Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?